MediGene’s Veregen® launched by Solvay in Germany   more
MediGene and Teva sign agreement to commercialize Veregen™ in Israel   more
MediGene nominates Dr. Thomas Werner to the Supervisory Board   more
MediGene AG presents future business plan at annual analyst conference   more

Drugs for the market

MediGene's vision is the expansion of the potentials in medicine
by means of utilizing biotechnology in a responsible manner.
We apply state-of-the-art technologies in the development of
innovative drugs for the treatment of cancer and autoimmune
diseases. MediGene pursues the strategy of integrating all core
areas of a modern biopharmaceuticals company from research to
drug development and commercialization.